Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2024-05-22 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find enclosed publication of Q 4 FY 2024 results in newspapers.
Regulatory Filings Classification · 95% confidence The document is a letter dated 22/05/2024 addressed to stock exchanges (BSE and NSE) regarding the publication of extracts of standalone and consolidated audited financial results for the quarter and financial year ended 31 March 2024. It mentions that these extracts were approved by the Board of Directors on 21 May 2024 and have been published in newspapers. The document is essentially a notification about the publication of financial results extracts, not the full financial report itself. The length is 6212 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or analysis included, only a statement about the publication of results. Therefore, this document fits the category of Regulatory Filings (RNS) as a general regulatory announcement about financial results publication, not the full Annual Report or Earnings Release.
2024-05-22 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter dated 22/05/2024 addressed to stock exchanges (BSE and NSE) regarding the publication of extracts of standalone and consolidated audited financial results for the quarter and financial year ended 31 March 2024. It mentions that these extracts were approved by the Board of Directors on 21 May 2024 and published in newspapers. The document is essentially a notification about the publication of financial results extracts, not the full financial report itself. The length is 6212 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or analysis included, only a statement about the publication of results extracts. Therefore, this document fits the category of Regulatory Filings (RNS) as a general regulatory announcement about financial results publication, rather than the full Annual Report (10-K) or Interim Report (IR).
2024-05-22 English
Please find enclosed revised investors presentation.
Investor Presentation Classification · 100% confidence The document is titled 'Revised Investors Presentation (Q4’FY24) May, 2024' and is addressed to stock exchanges with references to financial performance for the quarter and financial year ended March 31, 2024. It explicitly states it is an investor presentation and contains detailed financial and operational performance data, business segments, and forward-looking statements. The document is about 15,000 characters long and contains detailed presentation content rather than just an announcement or a brief summary. It is not a full annual or quarterly report with formal financial statements but a presentation aimed at investors summarizing financial results and company strategy. Therefore, the document fits the category of an Investor Presentation (IP).
2024-05-22 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Revised Investors Presentation (Q4’FY24) May, 2024' and is addressed to stock exchanges with references to financial performance for the quarter and financial year ended March 31, 2024. The content includes detailed business segments, financial overview, operational performance, and forward-looking statements. It explicitly states it is an investor presentation and contains no full financial statements or audit reports. The document is about presenting financial and strategic information to investors, consistent with an Investor Presentation. It is not an earnings release (which would be shorter and focused on key highlights), nor an annual or interim report (which would contain full financial statements). It is also not a regulatory filing or announcement of a report publication. Therefore, the classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support a high confidence score.
2024-05-22 English
Please find enclosed file
Regulatory Filings
2024-05-21 English
Please find enclosed press release titled ''Morepen Labs profit surges 143% while revenue grows 20% in FY24''
Earnings Release Classification · 95% confidence The document is a press release dated 21/05/2024 announcing Morepen Laboratories Limited's financial performance for the quarter and fiscal year ended 31st March 2024. It contains detailed financial highlights such as revenue, EBITDA, profit before tax, profit after tax, and EPS growth, along with business segment performance and future outlook commentary. The document is titled as a 'Press Release' and is addressed to stock exchanges, indicating it is an initial announcement of financial results rather than a comprehensive report. It does not contain full financial statements or detailed management discussion and analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). The length (10,695 characters) and content are consistent with an Earnings Release (ER), which typically summarizes key financial results and business highlights for a quarter or fiscal year. Therefore, the appropriate classification is Earnings Release (ER). FY 2024
2024-05-21 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.